Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07054736 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: XKH001 Injection
DRUG: XKH001 Placebo Injection

Sponsor

Zhejiang Kanova Biopharmaceutical Co., LTD